These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 4018736)

  • 1. Increased serum levels of hyaluronate in liver disease.
    Engström-Laurent A; Lööf L; Nyberg A; Schröder T
    Hepatology; 1985; 5(4):638-42. PubMed ID: 4018736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum hyaluronate in liver diseases: study by enzymoimmunological assay.
    Frébourg T; Delpech B; Bercoff E; Senant J; Bertrand P; Deugnier Y; Bourreille J
    Hepatology; 1986; 6(3):392-5. PubMed ID: 3710427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The extracellular matrix and liver disease: a study with enzymoimmunological assay].
    Gao F; Kong XT; Wang XL
    Zhonghua Nei Ke Za Zhi; 1994 Feb; 33(2):109-12. PubMed ID: 8070290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular weight of hyaluronate in the serum of patients with chronic liver disease.
    Murawaki Y; Ikuta Y; Idobe Y; Koda M; Kawasaki H
    Res Commun Mol Pathol Pharmacol; 1998 Feb; 99(2):207-16. PubMed ID: 9583094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum hyaluronate in primary biliary cirrhosis--a biochemical marker for progressive liver damage.
    Nyberg A; Engström-Laurent A; Lööf L
    Hepatology; 1988; 8(1):142-6. PubMed ID: 3338702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum hyaluronate and type III procollagen aminoterminal propeptide concentration in chronic liver disease. Relationship to cirrhosis and disease activity.
    Ramadori G; Zöhrens G; Manns M; Rieder H; Dienes HP; Hess G; Meyer KH; Büschenfelde Z
    Eur J Clin Invest; 1991 Jun; 21(3):323-30. PubMed ID: 1909636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is serum hyaluronan a helpful tool in the management of patients with liver diseases?
    Lindqvist U
    J Intern Med; 1997 Jul; 242(1):67-71. PubMed ID: 9260569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The clinic significance of serum hyaluronate and tumor necrosis factor alpha levels in liver diseases].
    Zou B; Ling Q; Huo J; Lin L; He J; Pan Y
    Hunan Yi Ke Da Xue Xue Bao; 1998; 23(1):97-9. PubMed ID: 10681811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum hyaluronate reflects hepatic sinusoidal capillarization.
    Ueno T; Inuzuka S; Torimura T; Tamaki S; Koh H; Kin M; Minetoma T; Kimura Y; Ohira H; Sata M
    Gastroenterology; 1993 Aug; 105(2):475-81. PubMed ID: 8335202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum beta 2-microglobulin levels in primary biliary cirrhosis.
    Nyberg A; Lööf L; Hällgren R
    Hepatology; 1985; 5(2):282-5. PubMed ID: 3884477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis.
    Parés A; Deulofeu R; Giménez A; Caballería L; Bruguera M; Caballería J; Ballesta AM; Rodés J
    Hepatology; 1996 Dec; 24(6):1399-403. PubMed ID: 8938169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum hyaluronate correlates with histological progression in alcoholic liver disease.
    Stickel F; Poeschl G; Schuppan D; Conradt C; Strenge-Hesse A; Fuchs FS; Hofmann WJ; Seitz HK
    Eur J Gastroenterol Hepatol; 2003 Sep; 15(9):945-50. PubMed ID: 12923365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of serum hyaluronate concentrations in patients with alcoholic liver disease.
    Tsutsumi M; Urashima S; Takase S; Ueshima Y; Tsuchishima M; Shimanaka K; Kawahara H
    Alcohol Clin Exp Res; 1997 Dec; 21(9):1716-21. PubMed ID: 9438536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-prandial serum hyaluronan concentration in patients with chronic liver disease.
    Idobe Y; Murawaki Y; Ikuta Y; Koda M; Kawasaki H
    Intern Med; 1998 Jul; 37(7):568-75. PubMed ID: 9711881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum hyaluronate level for predicting subclinical liver dysfunction after hepatectomy.
    Mizuguchi T; Katsuramaki T; Nobuoka T; Kawamoto M; Oshima H; Kawasaki H; Kikuchi H; Shibata C; Hirata K
    World J Surg; 2004 Oct; 28(10):971-6. PubMed ID: 15573250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical usefulness of serum matrix metalloproteinase-2 concentration in patients with chronic viral liver disease.
    Murawaki Y; Yamada S; Ikuta Y; Kawasaki H
    J Hepatol; 1999 Jun; 30(6):1090-8. PubMed ID: 10406188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Behavior of the serum electrolytes sodium and potassium in patients with cholelithiasis with reference to pathologic changes in the liver].
    Schmauss AK; Gerloff D; Poley FW
    Z Gesamte Inn Med; 1971 May; 26(10):327-31. PubMed ID: 5131401
    [No Abstract]   [Full Text] [Related]  

  • 18. Insulin-like growth factors (IGF) in liver disease: differential changes of IGF-I and IGF-II.
    Sheppard MS; Minuk GY; Bhaumick B; Bala RM
    Clin Invest Med; 1987 Mar; 10(2):49-53. PubMed ID: 3581545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyaluronic acid concentration in liver diseases.
    Gudowska M; Gruszewska E; Panasiuk A; Cylwik B; Flisiak R; Świderska M; Szmitkowski M; Chrostek L
    Clin Exp Med; 2016 Nov; 16(4):523-528. PubMed ID: 26354758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycocholic acid in chronic active hepatitis and mild liver diseases.
    Collazos J
    Clin Investig; 1993 Dec; 72(1):36-9. PubMed ID: 8136614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.